Tofacitinib Confers Excess Risk for Herpes Zoster

摘要

In patients with rheumatoid arthritis, shingles risk doubled when tofacitinib-treated patients also used glucocorticoids. Patients with rheumatoid arthritis (RA) often receive therapies that include JAK inhibitors, including tofacitinib (Xeljanz). However, studies have shown excess risk for herpes zoster (HZ) in patients who receive tofacitinib. In this study, researchers used the MarketScan and Medicare databases to determine how risk for shingles varied among 8000 tofacitinib-treated patients, according to concomitant use of methotrexate or glucocorticoids.